HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Xilio Therapeutics, Inc.

Contributing Author

Recent Articles by Xilio Therapeutics, Inc.

Jan-08
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates XLO GlobeNewswire
Nov-13
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results XLO GlobeNewswire
Nov-07
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting XLO GlobeNewswire
Nov-07
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting XLO GlobeNewswire
Nov-03
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Oct-30
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting XLO GlobeNewswire
Oct-03
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting XLO GlobeNewswire
Oct-02
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Sep-09
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead XLO GlobeNewswire
Aug-14
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results XLO GlobeNewswire
Aug-01
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jul-02
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jun-10
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors XLO GlobeNewswire
Jun-05
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering XLO GlobeNewswire
Jun-03
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jun-02
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering XLO GlobeNewswire
Jun-02
Xilio Therapeutics Announces Proposed Public Offering XLO GlobeNewswire
May-31
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer XLO GlobeNewswire
May-08
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results XLO GlobeNewswire
May-02
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.